Cooley Advises Spruce Biosciences on Separation of its CRHX-101 Program into Adrenyx Biosciences
November 10, 2026
November 10, 2026
PALO ALTO, California, Nov. 10 [Category: BizLaw/Legal] -- Cooley, a law firm, posted the following news release:
* * *
Cooley Advises Spruce Biosciences on Separation of its CRHX-101 Program into Adrenyx Biosciences
*
Cooley advised Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, on the separation of the co . . .
* * *
Cooley Advises Spruce Biosciences on Separation of its CRHX-101 Program into Adrenyx Biosciences
*
Cooley advised Spruce Biosciences, Inc., a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, on the separation of the co . . .